SCHEMBL2383243

SCHEMBL2383243

CCOC(=O)c1cccc(NCc2cc3ccccc3o2)c1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.55
CDC25B P30305 2/20 0.46
CDC25A P30304 1/20 0.46
CDC25C P30307 1/20 0.46
TSHR P16473 5/20 0.45
ALDH1A1 P00352 4/20 0.45
HSD17B10 Q99714 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MAOB P27338 1/20 0.44
NPC1 O15118 4/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
MAOA P21397 1/20 0.43
MAPK1 P28482 2/20 0.43
MAPT P10636 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382676 0.87 RAB9A (0.48) RAB9ATSHRALDH1A1HSD17B10MAOB
SCHEMBL2383952 0.84 LMNA (0.43) RAB9ACDC25BCDC25ACDC25CTSHR
SCHEMBL2383240 0.84 RAB9A (0.53) RAB9AALDH1A1KDM4EMAOBNPC1
SCHEMBL2384948 0.81 NPC1 (0.45) RAB9ACDC25BCDC25ACDC25CTSHR
SCHEMBL2383546 0.81 ALDH1A1 (0.42) RAB9ACDC25BCDC25ACDC25CTSHR
SCHEMBL2382990 0.81 KMT2A (0.42) RAB9ACDC25BCDC25ACDC25CTSHR
SCHEMBL1403513 0.80 MAOA (0.48) RAB9ATSHRALDH1A1HSD17B10KDM4E
SCHEMBL3800594 0.79 KDM4E (0.54) TSHRALDH1A1HSD17B10KDM4EKMT2A
SCHEMBL2383520 0.75 TSHR (0.50) RAB9ATSHRALDH1A1HSD17B10NPC1
SCHEMBL2382953 0.74 LMNA (0.50) RAB9ATSHRALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012997-B2 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION (US) 2011-09-06 US disclosed
EP-2168958-A1 Isoindole-Imide Compounds, Compositions And Uses Thereof CELGENE CORPORATION (US) 2010-03-31 EP disclosed
US-20090286986-A1 ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF CELGENE CORPORATION 2009-11-19 US disclosed
US-7576104-B2 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION (US) 2009-08-18 US disclosed
EP-1767533-A1 N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor CELGENE CORPORATION (US) 2007-03-28 EP disclosed
US-7091353-B2 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION (US) 2006-08-15 US disclosed
US-20060025597-A1 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION 2006-02-02 US disclosed
EP-1363900-A1 ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS CELGENE CORPORATION (US) 2003-11-26 EP disclosed
US-20030096841-A1 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION 2003-05-22 US disclosed
WO-2002059106-A1 ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF CELGENE CORPORATION (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286986-A1 ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF TNF, IKZF3, TNFRSF1A RAB9A 996/4885CDC25B 1315/4885CDC25A 1324/4885
US-20060025597-A1 Isoindole-imide compounds, compositions, and uses thereof TNF, IKZF3, TNFRSF1A RAB9A 996/4885CDC25B 1315/4885CDC25A 1324/4885
US-20030096841-A1 Isoindole-imide compounds, compositions, and uses thereof TNF, IKZF3, IKZF1 RAB9A 1120/4885CDC25B 1354/4885CDC25A 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.